Testicular function after radioiodine therapy for thyroid carcinoma
Radiotherapy can cause infertility in both men and women. However, few data are available concerning the effects of radioiodine therapy for thyroid carcinoma on testicular function. We investigated 25 men (age 23-73 years) with differentiated thyroid carcinoma in a longitudinal prospective trial. Fo...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine 2000-05, Vol.27 (5), p.503-507 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 507 |
|---|---|
| container_issue | 5 |
| container_start_page | 503 |
| container_title | European journal of nuclear medicine |
| container_volume | 27 |
| creator | WICHERS, M BENZ, E PALMEDO, H BIERSACK, H. J GRÜNWALD, F KLINGMÜLLER, D |
| description | Radiotherapy can cause infertility in both men and women. However, few data are available concerning the effects of radioiodine therapy for thyroid carcinoma on testicular function. We investigated 25 men (age 23-73 years) with differentiated thyroid carcinoma in a longitudinal prospective trial. Follicle-stimulating hormone (FSH), inhibin B, luteinising hormone (LH) and testosterone were measured before (n = 25) and 3 months (n = 11), 6 months (n = 18), 12 months (n = 22), and 18 months (n = 18) after radioiodine therapy [radioiodine dose (mean +/- SEM): 9.8+/-0.89 GBq]. Before therapy, FSH was 5.4+/-0.77 IU/l; it increased significantly (P |
| doi_str_mv | 10.1007/s002590050535 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1026698298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2709433911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-96c4f5652db664c8653d091617da0ecb31bd9074085163a6d7802c724e0ebc723</originalsourceid><addsrcrecordid>eNpV0E1LAzEQBuAgiq3Vo1dZ0Ovq5Ds5yuIXFLzU85JNspjSbmqye-i_N9KCepo5PMy8vAhdY7jHAPIhAxCuAThwyk_QHAusawlKn6I5UAa10FrO0EXOawBgjPJzNMOgOFXA5qhZ-TwGO21MqvppsGOIQ2X60acqGRdiiC4Mvho_fTK7fdXHVPZ9isFV1iQbhrg1l-isN5vsr45zgT6en1bNa718f3lrHpe1ZZiMtRaW9Vxw4johmFWCUwe65JXOgLcdxZ3TIFnJhgU1wkkFxErCPPiuTLpAt4e7uxS_ppK7XccpDeVli4EIoRXRqqj6oGyKOSfft7sUtibtC2p_Kmv_VVb8zfHq1G29-6MPHRVwdwQmW7PpkxlsyL-OcsmFoN9pY3G8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026698298</pqid></control><display><type>article</type><title>Testicular function after radioiodine therapy for thyroid carcinoma</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>WICHERS, M ; BENZ, E ; PALMEDO, H ; BIERSACK, H. J ; GRÜNWALD, F ; KLINGMÜLLER, D</creator><creatorcontrib>WICHERS, M ; BENZ, E ; PALMEDO, H ; BIERSACK, H. J ; GRÜNWALD, F ; KLINGMÜLLER, D</creatorcontrib><description>Radiotherapy can cause infertility in both men and women. However, few data are available concerning the effects of radioiodine therapy for thyroid carcinoma on testicular function. We investigated 25 men (age 23-73 years) with differentiated thyroid carcinoma in a longitudinal prospective trial. Follicle-stimulating hormone (FSH), inhibin B, luteinising hormone (LH) and testosterone were measured before (n = 25) and 3 months (n = 11), 6 months (n = 18), 12 months (n = 22), and 18 months (n = 18) after radioiodine therapy [radioiodine dose (mean +/- SEM): 9.8+/-0.89 GBq]. Before therapy, FSH was 5.4+/-0.77 IU/l; it increased significantly (P<0.001) to 21.3+/-2.4 IU/l after 6 months and fell to 7.4+/-1.3 IU/l after 18 months (normal range: 1.8-9.2 IU/l). Inhibin B was significantly decreased (P<0.001) from 178+/-25.3 pg/ml before therapy to 22.2+/-5.5 pg/ml after 3 and 29.4+/-5.7 pg/ml after 6 months and rose to 154+/-23.3 pg/ml after 18 months (normal range 75-350 pg/ml). LH and testosterone were within the normal range during the whole study (1.6-9.2 IU/l and 10.4-34.7 nmol/l, respectively). LH was significantly increased (P<0.001) from 2.8+/-0.33 IU/l before therapy to 5.9+/-0.69 IU/l 6 months after therapy and then fell slowly to 4.0+/-0.45 IU/l after 18 months. Total testosterone was significantly increased (P<0.01) from 12.8+/-0.99 nmol/l at baseline to 19.8+/-1.7 nmol/l after 12 months and 19.6+/-1.7 nmol/l after 18 months. The testosterone/LH ratio (normal range: 3.3-17.9 nmol/IU) fell from 5.8+/-0.66 nmol/IU to 3.0+/-0.36 nmol/IU after 3 months (P<0.01); it remained close to the latter value after 6 months (3.4+/-0.49 nmol/IU) and then rose to 5.5+/-0.6 nmol/IU after 18 months. In conclusion, 3 and 6 months after radioiodine therapy all patients showed elevated FSH and decreased inhibin B levels, reflecting severely impaired spermatogenesis. At the same time a compensated insufficiency of the Leydig cell function was observed. Eighteen months after the last radioiodine therapy, mean values of gonadal function had completely recovered.</description><identifier>ISSN: 0340-6997</identifier><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s002590050535</identifier><identifier>PMID: 10853804</identifier><identifier>CODEN: EJNMD9</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Carcinoma - pathology ; Carcinoma - radiotherapy ; Carcinoma, Papillary - pathology ; Carcinoma, Papillary - radiotherapy ; Carcinoma, Papillary, Follicular - pathology ; Carcinoma, Papillary, Follicular - radiotherapy ; Endocrine glands ; Endocrinopathies ; Follicle Stimulating Hormone - blood ; Humans ; Inhibins - blood ; Iodine Radioisotopes - adverse effects ; Iodine Radioisotopes - therapeutic use ; Leydig Cells - radiation effects ; Luteinizing Hormone - blood ; Male ; Malignant tumors ; Medical sciences ; Middle Aged ; Organ Size - radiation effects ; Radiotherapy - adverse effects ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Spermatogenesis - radiation effects ; Spermatozoa - radiation effects ; Testis - metabolism ; Testis - physiology ; Testis - radiation effects ; Testosterone - blood ; Thyroid Neoplasms - pathology ; Thyroid Neoplasms - radiotherapy ; Thyroid. Thyroid axis (diseases) ; Time Factors</subject><ispartof>European journal of nuclear medicine, 2000-05, Vol.27 (5), p.503-507</ispartof><rights>2000 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-96c4f5652db664c8653d091617da0ecb31bd9074085163a6d7802c724e0ebc723</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1357566$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10853804$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WICHERS, M</creatorcontrib><creatorcontrib>BENZ, E</creatorcontrib><creatorcontrib>PALMEDO, H</creatorcontrib><creatorcontrib>BIERSACK, H. J</creatorcontrib><creatorcontrib>GRÜNWALD, F</creatorcontrib><creatorcontrib>KLINGMÜLLER, D</creatorcontrib><title>Testicular function after radioiodine therapy for thyroid carcinoma</title><title>European journal of nuclear medicine</title><addtitle>Eur J Nucl Med</addtitle><description>Radiotherapy can cause infertility in both men and women. However, few data are available concerning the effects of radioiodine therapy for thyroid carcinoma on testicular function. We investigated 25 men (age 23-73 years) with differentiated thyroid carcinoma in a longitudinal prospective trial. Follicle-stimulating hormone (FSH), inhibin B, luteinising hormone (LH) and testosterone were measured before (n = 25) and 3 months (n = 11), 6 months (n = 18), 12 months (n = 22), and 18 months (n = 18) after radioiodine therapy [radioiodine dose (mean +/- SEM): 9.8+/-0.89 GBq]. Before therapy, FSH was 5.4+/-0.77 IU/l; it increased significantly (P<0.001) to 21.3+/-2.4 IU/l after 6 months and fell to 7.4+/-1.3 IU/l after 18 months (normal range: 1.8-9.2 IU/l). Inhibin B was significantly decreased (P<0.001) from 178+/-25.3 pg/ml before therapy to 22.2+/-5.5 pg/ml after 3 and 29.4+/-5.7 pg/ml after 6 months and rose to 154+/-23.3 pg/ml after 18 months (normal range 75-350 pg/ml). LH and testosterone were within the normal range during the whole study (1.6-9.2 IU/l and 10.4-34.7 nmol/l, respectively). LH was significantly increased (P<0.001) from 2.8+/-0.33 IU/l before therapy to 5.9+/-0.69 IU/l 6 months after therapy and then fell slowly to 4.0+/-0.45 IU/l after 18 months. Total testosterone was significantly increased (P<0.01) from 12.8+/-0.99 nmol/l at baseline to 19.8+/-1.7 nmol/l after 12 months and 19.6+/-1.7 nmol/l after 18 months. The testosterone/LH ratio (normal range: 3.3-17.9 nmol/IU) fell from 5.8+/-0.66 nmol/IU to 3.0+/-0.36 nmol/IU after 3 months (P<0.01); it remained close to the latter value after 6 months (3.4+/-0.49 nmol/IU) and then rose to 5.5+/-0.6 nmol/IU after 18 months. In conclusion, 3 and 6 months after radioiodine therapy all patients showed elevated FSH and decreased inhibin B levels, reflecting severely impaired spermatogenesis. At the same time a compensated insufficiency of the Leydig cell function was observed. Eighteen months after the last radioiodine therapy, mean values of gonadal function had completely recovered.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - radiotherapy</subject><subject>Carcinoma, Papillary - pathology</subject><subject>Carcinoma, Papillary - radiotherapy</subject><subject>Carcinoma, Papillary, Follicular - pathology</subject><subject>Carcinoma, Papillary, Follicular - radiotherapy</subject><subject>Endocrine glands</subject><subject>Endocrinopathies</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Humans</subject><subject>Inhibins - blood</subject><subject>Iodine Radioisotopes - adverse effects</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Leydig Cells - radiation effects</subject><subject>Luteinizing Hormone - blood</subject><subject>Male</subject><subject>Malignant tumors</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Organ Size - radiation effects</subject><subject>Radiotherapy - adverse effects</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Spermatogenesis - radiation effects</subject><subject>Spermatozoa - radiation effects</subject><subject>Testis - metabolism</subject><subject>Testis - physiology</subject><subject>Testis - radiation effects</subject><subject>Testosterone - blood</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid Neoplasms - radiotherapy</subject><subject>Thyroid. Thyroid axis (diseases)</subject><subject>Time Factors</subject><issn>0340-6997</issn><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpV0E1LAzEQBuAgiq3Vo1dZ0Ovq5Ds5yuIXFLzU85JNspjSbmqye-i_N9KCepo5PMy8vAhdY7jHAPIhAxCuAThwyk_QHAusawlKn6I5UAa10FrO0EXOawBgjPJzNMOgOFXA5qhZ-TwGO21MqvppsGOIQ2X60acqGRdiiC4Mvho_fTK7fdXHVPZ9isFV1iQbhrg1l-isN5vsr45zgT6en1bNa718f3lrHpe1ZZiMtRaW9Vxw4johmFWCUwe65JXOgLcdxZ3TIFnJhgU1wkkFxErCPPiuTLpAt4e7uxS_ppK7XccpDeVli4EIoRXRqqj6oGyKOSfft7sUtibtC2p_Kmv_VVb8zfHq1G29-6MPHRVwdwQmW7PpkxlsyL-OcsmFoN9pY3G8</recordid><startdate>20000501</startdate><enddate>20000501</enddate><creator>WICHERS, M</creator><creator>BENZ, E</creator><creator>PALMEDO, H</creator><creator>BIERSACK, H. J</creator><creator>GRÜNWALD, F</creator><creator>KLINGMÜLLER, D</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20000501</creationdate><title>Testicular function after radioiodine therapy for thyroid carcinoma</title><author>WICHERS, M ; BENZ, E ; PALMEDO, H ; BIERSACK, H. J ; GRÜNWALD, F ; KLINGMÜLLER, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-96c4f5652db664c8653d091617da0ecb31bd9074085163a6d7802c724e0ebc723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - radiotherapy</topic><topic>Carcinoma, Papillary - pathology</topic><topic>Carcinoma, Papillary - radiotherapy</topic><topic>Carcinoma, Papillary, Follicular - pathology</topic><topic>Carcinoma, Papillary, Follicular - radiotherapy</topic><topic>Endocrine glands</topic><topic>Endocrinopathies</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Humans</topic><topic>Inhibins - blood</topic><topic>Iodine Radioisotopes - adverse effects</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Leydig Cells - radiation effects</topic><topic>Luteinizing Hormone - blood</topic><topic>Male</topic><topic>Malignant tumors</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Organ Size - radiation effects</topic><topic>Radiotherapy - adverse effects</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Spermatogenesis - radiation effects</topic><topic>Spermatozoa - radiation effects</topic><topic>Testis - metabolism</topic><topic>Testis - physiology</topic><topic>Testis - radiation effects</topic><topic>Testosterone - blood</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid Neoplasms - radiotherapy</topic><topic>Thyroid. Thyroid axis (diseases)</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WICHERS, M</creatorcontrib><creatorcontrib>BENZ, E</creatorcontrib><creatorcontrib>PALMEDO, H</creatorcontrib><creatorcontrib>BIERSACK, H. J</creatorcontrib><creatorcontrib>GRÜNWALD, F</creatorcontrib><creatorcontrib>KLINGMÜLLER, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WICHERS, M</au><au>BENZ, E</au><au>PALMEDO, H</au><au>BIERSACK, H. J</au><au>GRÜNWALD, F</au><au>KLINGMÜLLER, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Testicular function after radioiodine therapy for thyroid carcinoma</atitle><jtitle>European journal of nuclear medicine</jtitle><addtitle>Eur J Nucl Med</addtitle><date>2000-05-01</date><risdate>2000</risdate><volume>27</volume><issue>5</issue><spage>503</spage><epage>507</epage><pages>503-507</pages><issn>0340-6997</issn><issn>1619-7070</issn><eissn>1619-7089</eissn><coden>EJNMD9</coden><abstract>Radiotherapy can cause infertility in both men and women. However, few data are available concerning the effects of radioiodine therapy for thyroid carcinoma on testicular function. We investigated 25 men (age 23-73 years) with differentiated thyroid carcinoma in a longitudinal prospective trial. Follicle-stimulating hormone (FSH), inhibin B, luteinising hormone (LH) and testosterone were measured before (n = 25) and 3 months (n = 11), 6 months (n = 18), 12 months (n = 22), and 18 months (n = 18) after radioiodine therapy [radioiodine dose (mean +/- SEM): 9.8+/-0.89 GBq]. Before therapy, FSH was 5.4+/-0.77 IU/l; it increased significantly (P<0.001) to 21.3+/-2.4 IU/l after 6 months and fell to 7.4+/-1.3 IU/l after 18 months (normal range: 1.8-9.2 IU/l). Inhibin B was significantly decreased (P<0.001) from 178+/-25.3 pg/ml before therapy to 22.2+/-5.5 pg/ml after 3 and 29.4+/-5.7 pg/ml after 6 months and rose to 154+/-23.3 pg/ml after 18 months (normal range 75-350 pg/ml). LH and testosterone were within the normal range during the whole study (1.6-9.2 IU/l and 10.4-34.7 nmol/l, respectively). LH was significantly increased (P<0.001) from 2.8+/-0.33 IU/l before therapy to 5.9+/-0.69 IU/l 6 months after therapy and then fell slowly to 4.0+/-0.45 IU/l after 18 months. Total testosterone was significantly increased (P<0.01) from 12.8+/-0.99 nmol/l at baseline to 19.8+/-1.7 nmol/l after 12 months and 19.6+/-1.7 nmol/l after 18 months. The testosterone/LH ratio (normal range: 3.3-17.9 nmol/IU) fell from 5.8+/-0.66 nmol/IU to 3.0+/-0.36 nmol/IU after 3 months (P<0.01); it remained close to the latter value after 6 months (3.4+/-0.49 nmol/IU) and then rose to 5.5+/-0.6 nmol/IU after 18 months. In conclusion, 3 and 6 months after radioiodine therapy all patients showed elevated FSH and decreased inhibin B levels, reflecting severely impaired spermatogenesis. At the same time a compensated insufficiency of the Leydig cell function was observed. Eighteen months after the last radioiodine therapy, mean values of gonadal function had completely recovered.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>10853804</pmid><doi>10.1007/s002590050535</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6997 |
| ispartof | European journal of nuclear medicine, 2000-05, Vol.27 (5), p.503-507 |
| issn | 0340-6997 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_journals_1026698298 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Biological and medical sciences Carcinoma - pathology Carcinoma - radiotherapy Carcinoma, Papillary - pathology Carcinoma, Papillary - radiotherapy Carcinoma, Papillary, Follicular - pathology Carcinoma, Papillary, Follicular - radiotherapy Endocrine glands Endocrinopathies Follicle Stimulating Hormone - blood Humans Inhibins - blood Iodine Radioisotopes - adverse effects Iodine Radioisotopes - therapeutic use Leydig Cells - radiation effects Luteinizing Hormone - blood Male Malignant tumors Medical sciences Middle Aged Organ Size - radiation effects Radiotherapy - adverse effects Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Spermatogenesis - radiation effects Spermatozoa - radiation effects Testis - metabolism Testis - physiology Testis - radiation effects Testosterone - blood Thyroid Neoplasms - pathology Thyroid Neoplasms - radiotherapy Thyroid. Thyroid axis (diseases) Time Factors |
| title | Testicular function after radioiodine therapy for thyroid carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T22%3A50%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Testicular%20function%20after%20radioiodine%20therapy%20for%20thyroid%20carcinoma&rft.jtitle=European%20journal%20of%20nuclear%20medicine&rft.au=WICHERS,%20M&rft.date=2000-05-01&rft.volume=27&rft.issue=5&rft.spage=503&rft.epage=507&rft.pages=503-507&rft.issn=0340-6997&rft.eissn=1619-7089&rft.coden=EJNMD9&rft_id=info:doi/10.1007/s002590050535&rft_dat=%3Cproquest_cross%3E2709433911%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026698298&rft_id=info:pmid/10853804&rfr_iscdi=true |